Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer.
Gebbia V, Guarini A, Piazza D, Bertani A, Spada M, Verderame F, Sergi C, Potenza E, Fazio I, Blasi L, La Sala A, Mortillaro G, Roz E, Marchese R, Chiarenza M, Soto-Parra H, Valerio MR, Agneta G, Amato C, Lipari H, Baldari S, Ferraù F, Di Grazia A, Mancuso G, Rizzo S, Firenze A. Gebbia V, et al. Among authors: blasi l. Pulm Ther. 2021 Dec;7(2):295-308. doi: 10.1007/s41030-021-00163-8. Epub 2021 Jun 4. Pulm Ther. 2021. PMID: 34089169 Free PMC article. Review.
Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.
Adamo V, Ricciardi GRR, Giuffrida D, Scandurra G, Russo A, Blasi L, Spadaro P, Iacono C, Soto Parra HJ, Savarino A, Ferraú F, Zerilli F, Verderame F, Butera A, Santangelo C, Franchina V, Caruso M. Adamo V, et al. Among authors: blasi l. Ther Adv Med Oncol. 2019 Dec 19;11:1758835919895755. doi: 10.1177/1758835919895755. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31903098 Free PMC article.
Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: a WhatsApp messenger-based report from the Italian College of Chief Medical Oncologists.
Blasi L, Bordonaro R, Borsellino N, Butera A, Caruso M, Cordio S, Liborio DC, Ferraù F, Giuffrida D, Parra HS, Spada M, Tralongo P, Valenza R, Verderame F, Vitello S, Zerilli F, Piazza D, Firenze A, Gebbia V. Blasi L, et al. Ecancermedicalscience. 2020 May 15;14:1046. doi: 10.3332/ecancer.2020.1046. eCollection 2020. Ecancermedicalscience. 2020. PMID: 32565899 Free PMC article.
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis.
Gebbia V, Aiello MM, Banna G, Blanco G, Blasi L, Borsellino N, Giuffrida D, Mauro ML, Mancuso G, Piazza D, Savio G, Parra HS, Valerio MR, Verderame F, Vigneri P. Gebbia V, et al. Among authors: blasi l. Ecancermedicalscience. 2020 Sep 29;14:1113. doi: 10.3332/ecancer.2020.1113. eCollection 2020. Ecancermedicalscience. 2020. PMID: 33144881 Free PMC article.
Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study.
Orlando L, Giotta F, Lorusso V, De Vita F, Filippelli G, Maiello E, Riccardi F, Pappagallo GL, Fedele P, Gebbia N, Verderame F, Barni S, Blasi L, Pisconti S, Colucci G, Cinieri S. Orlando L, et al. Among authors: blasi l. Future Oncol. 2014 Apr;10(5):725-33. doi: 10.2217/fon.13.186. Future Oncol. 2014. PMID: 24799054 Clinical Trial.
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.
Bronte G, Franchina T, Alù M, Sortino G, Celesia C, Passiglia F, Savio G, Laudani A, Russo A, Picone A, Rizzo S, De Tursi M, Gambale E, Bazan V, Natoli C, Blasi L, Adamo V, Russo A. Bronte G, et al. Among authors: blasi l. Oncotarget. 2016 Jun 14;7(24):35803-35812. doi: 10.18632/oncotarget.8130. Oncotarget. 2016. PMID: 26993607 Free PMC article.
89 results